Santé log10h
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...
Santé log10h
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease; ARISE will evaluate the efficacy of solengepr ...
Santé log9h
Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024
Both posters will be available on the Rectify website at https://rectifypharma.com/publications/.
Santé log9h
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, ...
Santé log10h
RESTEM Presents Phase 1 Data of its ULSC Program in Polymyositis/Dermatomyositis at ACR Convergence 2024
The presentation entitled, “ Safety and Efficacy Data from a Phase I Trial of Umbilical Lining Stem Cells (ULSCs) in Adult Dermatomyositis/Polymyositis ” was delivered by Michael R Bubb, M.D., ...
Santé log1d
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...
Santé log10h
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the “Hearings Panel”) has cancelled ...
Santé log1d
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and ...
Santé log9h
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and ...
Santé log9h
Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders
The Company strongly encourages all of its stockholders to read the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on October 18, ...
Santé log9h
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
We are pleased to complete the last subject visit in our Phase 1 trial of MBX 1416 in healthy adults and extend our sincere appreciation to the participants, investigators and clinical team for their ...
Santé log9h
Sharps Regains Nasdaq Listing Compliance
We view our listing on Nasdaq to be extremely important to us as a Company as it offers the Company and its shareholders the best opportunity for the future. Further, we want to thank the shareholders ...